Nuevolution CEO: We hit a great window
Denmark’s Nuevolution is gearing up to float its shares on the First North exchange, but that is merely the first step. The money from the IPO should push business along and ensure that the biotech company can move up to the main exchange next year, says CEO Alex Haahr Gouliaev.
BY LONNI LYNGE
Monday saw the beginning of a major road show for Denmark’s Nuevolution. The biotech company headed by Alex Haahr Gouliaev is gearing up for an IPO on the First North Premier in Stockholm in December. The aim is to raise SEK 225 million (USD 25.67 million), which will be used to accelerate the company’s projects.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Danish biotech company still considers IPO
For abonnenter
Nuevolution CEO: J&J deal is stamp of approval
For abonnenter
Nuevolution strikes deal with Swiss pharma giant
For abonnenter
